A5089983989- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Prostate Cancer Diagnosis and Treatment
- Cinema and Media Studies
- Cancer, Lipids, and Metabolism
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Cancer, Hypoxia, and Metabolism
- Genetic factors in colorectal cancer
- Poisoning and overdose treatments
- Cannabis and Cannabinoid Research
- Historical Economic and Social Studies
- Chronic Myeloid Leukemia Treatments
- Medical Imaging Techniques and Applications
- Historical and Architectural Studies
- Cancer Diagnosis and Treatment
- COVID-19 epidemiological studies
- SARS-CoV-2 and COVID-19 Research
- Cancer Treatment and Pharmacology
- Asian Industrial and Economic Development
- Neurological and metabolic disorders
- Political and Economic history of UK and US
- Hormonal and reproductive studies
Tulane University
2016-2025
McGill University
2002-2024
University of Arizona
2022-2023
University Medical Center
1993-2023
Maine Department of Marine Resources
2023
Massachusetts General Hospital
2023
Harvard University
2023
Louisiana Cancer Research Center
2023
Agency for Toxic Substances and Disease Registry
2007-2022
Banner - University Medical Center Phoenix
2022
Background Morgellons is a poorly characterized constellation of symptoms, with the primary manifestations involving skin. We conducted an investigation this unexplained dermopathy to characterize clinical and epidemiologic features explore potential etiologies. Methods A descriptive study was among persons at least 13 years age enrolled in Kaiser Permanente Northern California (KPNC) during 2006–2008. case defined as self-reported emergence fibers or materials from skin accompanied by...
The goal of this study is to evaluate germline genetic variants in African American men with metastatic prostate cancer as compared those Caucasian an effort understand the role factors these populations.African and who had testing using multigene panels were used generate comparisons. Germline results, clinical parameters, family histories between two populations analyzed.A total 867 patients included retrospective study, including 188 669 patients. There was no significant difference...
Most studies on health disparities during the coronavirus disease 2019 (COVID-19) pandemic focused reported cases and deaths, which are influenced by testing availability access to care. This study aimed examine severe acute respiratory syndrome 2 (SARS-CoV-2) antibody seroprevalence in United States its associations with race/ethnicity, rurality, social vulnerability over time.This repeated cross-sectional used data from blood donations 50 states Washington, DC, July 2020 through June 2021....
Ziel/Aim: In PSMAfore (NCT04689828), [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolonged rPFS versus androgen receptor pathway inhibitor (ARPI) change in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). We now present the time to symptomatic skeletal events (SSE) and worsening (TTW) health-related quality of life (HRQoL) pain at third interim analysis (data cutoff, 27 Feb 2024).
5003 Background: [ 177 Lu]Lu-PSMA-617 ( Lu-PSMA-617) prolonged radiographic progression-free survival vs change of androgen receptor pathway inhibitor (ARPI) in taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) PSMAfore (NCT04689828). We now present health-related quality life (HRQoL) and pain outcomes at second interim analysis. Methods: Eligible had mCRPC, were candidates for ARPI after progression on one prior ARPI, ≥1 PSMA-positive no exclusionary...
Abstract The Maine Department of Marine Resources (MEDMR) is a state agency tasked with developing, conserving, researching, and promoting commercial recreational marine fisheries across Maine’s vast coastline. Close collaborations industry members in each the 30 or more that support coastal economy are central to MEDMR’s efforts address this suite tasks. Here we reflect on recent decades MEDMR's work demonstrate how MEDMR research programmes preparing for an uncertain future through lens...
5072 Background: ACIS was an international phase III trial comparing apalutamide (A) plus abiraterone acetate and prednisone (AAP) to AAP in patients (pts) with mCRPC. Recognizing that lack of diversity clinical trials is a major challenge real-world translation outcomes, we purposely designed PANTHER oversample Black pts compared our catchment area demographics estimate outcomes among White mCRPC, accrued parallel, single arm cohorts treated A+AAP. Here report the long term radiographic...
4564 Background: For patients (pts) with MIBC who are cisplatin-ineligible and undergoing radical cystectomy pelvic lymph node dissection (RC+PLND), no neoadjuvant treatment options have been shown to improve survival. Enfortumab vedotin (EV) is an antibody-drug conjugate directed Nectin-4, which highly expressed in urothelial cancer. EV, alone combination w/ pembrolizumab, has OS vs chemotherapy pts previously treated untreated locally advanced or metastatic cancer, respectively (Powles...
5074 Background: PC commonly expresses PSMA and has dose-responsive radiosensitivity. 177 Lu-based radioligands usually use an empiric dosing regimen. This 1st dose-escalation study of Lu-PSMA-617 employed a dose-dense fractionation schedule intended to allow delivery higher total doses overcome radioresistance due repopulation. Here, we report mature results the study. Methods: Progressive mCRPC following > 1 potent ARPI (e.g., abi/enza) chemo (or unfit/refuse taxane) without limit #...
Abiraterone is an important agent in the treatment of advanced prostate cancer. Early changes prostate-specific antigen while on abiraterone patients with metastatic castrate-resistant cancer potentially have financial and health implications for patients. Limited data available early change subsequent survival given phase III trials did not measure before 12 weeks.A single-center retrospective study was performed. Metastatic treated (without prior enzalutamide) at Tulane Cancer Center were...
Abstract Background Recent literature highlights the importance of germline genetic testing in prostate cancer (PCa) patients. Surprisingly, a review indicates that family history (FH) records are incomplete major published studies from Methods Prospective data were gathered 496 men single institution with personal PCa who underwent using panel at least 79 genes. Comprehensive first degree FH obtained all patients and analysis prevalent was assessed time sample collection. Results...
Bipolar androgen therapy (BAT) is a novel known to be effective in subset of men with metastatic castrate resistant prostate cancer (mCRPC). A better understanding responders and nonresponders BAT would useful clinicians considering for patients. Herein we analyze clinical genetic factors responders/nonresponders refine our regarding which patients benefit from this innovative therapy.mCRPC were assessed response or no BAT. Patients PSA declines greater than 50% baseline after 2 more doses...
Cancer cluster investigations rarely receive significant public health resource allocations due to numerous inherent challenges and the limited success of past efforts. In 2008, a polycythemia vera, rare blood cancer with unknown etiology, was identified in northeast Pennsylvania. A multidisciplinary group federal state agencies, academic institutions, local healthcare providers subsequently developed multifaceted research portfolio designed better understand cause cluster. This agenda...
Treatment options for men with metastatic castration-resistant prostate cancer are rapidly changing. In addition to novel anti-androgens and taxane-based chemotherapy, radiopharmaceuticals having an increasing role. Although calcium-mimetic theranostics have been in use years, newer approaches molecularly targeted radiation therapy by conjugating isotopes prostate-specific membrane antigen (PSMA) so doing directly target cells; 177Lutetium-PSMA-617 is perhaps the best-known member of this...